Karo Bio Selects Reaxys and Reaxys Medicinal Chemistry to Support Chemists in Research and Development
Comprehensive and relevant chemistry and bioactivity related content
reduces research timescales and supports rapid user adoption
Comprehensive and relevant chemistry and bioactivity related content reduces research timescales and supports rapid user adoption
world-leading provider of scientific, technical and medical information
products and services, today announced that Karo
Bio, a developer of innovative drugs for large medical needs, has started
to use Reaxys® and Reaxys®
Medicinal Chemistry. Karo Bio has chosen the solutions to support its
chemists in their research and development objectives, ensuring they have quick
and easy access to state of the art chemistry information.
"Comprehensive content is critical to our chemists and the Reaxys solutions give them more relevant results in a single search than other solutions could offer," said Maria Sjöberg, Chief Scientific Officer at Karo Bio. "Not only do our chemists have access to more data, including biological as well as chemical information, but the content is more applicable to their research. We expect the availability of the Reaxys Medicinal Chemistry information alone will reduce research and development time by approximately 20 percent."
Reaxys, with its recent expansion of chemistry data and capabilities now encompassing content of over 16,000 periodicals, is recognized by users as having the deepest and richest fact-base of experimentally measured chemistry data. Reaxys Medicinal Chemistry offers access to data from a vast repository of peer-reviewed journal articles and patents and is interoperable with Reaxys. Adding this content to Karo Bio's information sources means that chemists will have readily available access to relevant information. That, coupled with the flexibility of the search function and the way results are presented, will enable chemists to more quickly identify and prioritize viable compounds, helping reduce the time it takes to bring innovative drugs to market.
"Researchers in life sciences face an ever growing challenge in making confident and successful decisions in a changing landscape," said Dr. Juergen Swienty-Busch, Head of Product Management for Reaxys. "Karo Bio has a unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals. We are excited that the Reaxys solutions will play a part in increasing the speed at which these projects to discover innovative compounds come to fruition."
Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science Solutions, a suite of interoperable, domain-specific, decision support tools which span the discovery and development workflow; including ScienceDirect, Scopus, TargetInsights, Pathway Studio, PharmaPendium, QUOSA and Embase.
For further information go to www.elsevier.com/reaxys.
# # #
About Karo Bio
Karo Bio is a pharmaceutical company focused on the research and development of innovative drugs for large medical needs. The company runs a number of drug development projects within the indication areas neuropsychiatry, inflammation, autoimmune diseases and cancer. An important foundation for the company's activities is its unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals, as well as related mechanisms of action. Karo Bio is based in Huddinge, Sweden, has around 43 employees and is listed on NASDAQ OMX Stockholm. www.karobio.com
Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit Reaxys.
Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries. www.elsevier.com
+31 20 485 2247